The signs and symptoms of ankylosing spondylitis (AS) respond inadequately to nonsteroidal antiinXammatory drugs, corticosteroids, and disease modifying antirheumatic drugs in quite a number of patients. Tumor necrosis factor inhibitors have demonstrated to be of value in reducing AS disease activity in clinical trials. The eYcacy and safety of both etanercept and inXiximab in patients with ankylosing spondylitis were compared in a 2-year open label randomised study. Our results are consistent with a signiWcant more rapid clinical improvement in the inXiximab treated group. Treatment with both etanercept and inXiximab at the end of the study was eVective, safe, and well tolerated.
Introduction
Ankylosing spondylitis (AS) is a debilitating disease predominantly aVecting the spine characterized by axial skeletal ankylosis [1] . Therapeutic options for AS, such as non-steroidal anti-inXammatory drugs (NSAIDs), oVer temporary pain relief with little if any clinical beneWt on spinal mobility, and disease modifying antirheumatic drugs (DMARDs) do not appear to aVect the spinal involvement of AS [2] .
Tumor necrosis factor is a proinXammatory cytokine that appears to have a key role in the pathogenesis of AS inXammation [3] . Etanercept is a fully human recombinant protein, comprising two molecules of soluble TNF receptor p75 and the crystallisable fragment component of immunoglobulin G1, which speciWcally binds to and neutralizes TNF-alpha. Several clinical studies have shown that etanercept reduces disease activity in patients with spondyloarthropathies, including reactive arthritis and AS [4] [5] [6] [7] [8] . Similar results have been reported with inXiximab, a chimeric monoclonal antibody against TNF [9] [10] [11] [12] [13] [14] [15] . The aim of the present work was to compare the eYcacy and safety of both etanercept and inXiximab in patients with ankylosing spondylitis in a two-year open label randomised study.
Patients and methods
Fifty consecutive patients that fulWlled the modiWed New York criteria for the diagnosis of AS [16] were enrolled in the study. Patients had to be non responder to oral non-steroidal anti-inXammatory drugs and naïve for DMARDs or other TNF blocking agents. Patients with complete ankylosis (fusion) of the spine were excluded. Approval from an independent ethics committee was obtained, and all patients provided written informed consent to participate. Patients were randomised to receive alternatively etanercept or inXiximab with a ratio of 1:1. EYcacy and safety evaluations were performed at weeks 2, 4, 8, and 12 and then every 3 months until 2 years. Criteria for inclusion were: active disease for at least 3 months, a BASDAI >4 and a VAS for spinal pain score >4. Patients received etanercept at a 50 mg dose delivered subcutaneously weekly or inXiximab at 5 mg/kg at week 0, 2, 6 and every 6 weeks for a period of 102 weeks. The clinical response to etanercept or inXiximab was evaluated on the basis of response criteria recommended by the ASAS Working Group [17] . An ASAS 20 and 40 responder was deWned as a patient who showed at least 20 or 40% improvement from baseline and had an absolute improvement from baseline of at least 1 unit (on a scale of 0-10) in at least 3 of the following 4 assessment domains: patient's global assessment, spinal pain, function according to the Bath Ankylosing Spondylitis Functional Index (BASFI), and morning stiVness (the average of the last 2 questions of the BASDAI).
Disease activity was assessed bay the Bath Ankylosing Spondylitis Activity Index (BASDAI). Functional impairment was assessed by the ten item Bath Ankylosing Spondylitis Functional Index (BASFI). The BASMI is an aggregate score (ranging from 0 to 10) of patient mobility assessments, including tragus-to-wall lumbar Xexion (Schober test), cervical rotation, lumbar side Xexion, and intermalleolar distance [18, 19] . Chest expansion is the diVerence between the circumference of the chest in maximal inspiration and that in maximal expiration.
Patients were monitored for adverse events and abnormal laboratory test results over the course of the study. Vital signs were monitored, and standard hematology, serum chemistry, and urine analysis tests were evaluated.
Statistics
To compare mean diVerences between time points (week 0 vs. week 12, week 54 and week 104), a unpaired t-test was applied. In the case of skewed distributions [CRP and erythrocyte sedimentation rate (ESR)], the corresponding non-parametric test (Wilcoxon test) was used. McNemar test was applied in the case of proportions.
Results
A total of 50 patients were enrolled in the study; 25 were assigned to receive etanercept and 25 were assigned to inXiximab. The average age of patients was 32.2 § 8 years. 39 patients were male (79%) and the duration of symptoms was 15.6 § 8.7 years. The treatment groups had similar baseline disease activity scores and demographic characteristics (Table 1) . No patients discontinued therapies. Although the diVerence was not statistically signiWcant, more inXiximab patients than etanercept patients responded at the ASAS 20 level as early as week 2 but sustained diVerences were not evident up to week 12. After 12 weeks, 19 of 25 patients (75%) in the inXiximab group were ASAS 20 responders compared with 15 of 25 patients (60%) in the etanercept group (Fig. 1) . On the 12th week, 55% of patient treated with inXiximab and 43% of patients treated with etanercept were at the ASAS 40 level (Fig. 1) . At week 12 more inXiximab than etanercept treated patients achieved a signiWcantly reduction of BASDAI (4.8 vs. 5.9; p < 0.005 and 3.5 vs. 5.6; p < 0.005) (Fig. 2) , and of BASFI (3.5 vs. 5; p < 0.005) (Fig. 3) . Acute phase reactants, BASMI, SP and HAQ signiWcantly decreased in both group of patients from baseline during the observation period without diVerences between the two groups (not shown). Treatments were generally well tolerated and adverse events were mostly mild to moderate (Table 2 ). There were no discontinuations for safety reasons. In particular, there was no cases of opportunistic infections, tuberculosis, congestive heart disease, demyelinating disorders, lupus-like syndromes, and malignancy.
Discussion
TNF blocking agents are internationally considered to represent a major progress in the treatment of AS. Comparative studies with etanercept and inXiximab treatments were not yet published, however. A 50 mg dose of etanercept delivered subcutaneously weekly and 6 weeks infusion of inXiximab (5 mg/kg) produced rapid, signiWcant, and sustained improvement in multiple clinical and laboratory measures of AS. Although no signiWcant diVerences were observed at the end of the study, our results are consistent with a signiWcant more rapid clinical improvement in the inXiximab treated group. At week 12 in fact more inXiximab than etanercept treated patients achieved a signiWcantly reduction of BASDAI and BASFI, and there were also more responders in the inXiximab group at the ASAS 20 and ASAS 40 level. In general, improvements with both therapies were observed at 2 weeks and were sustained up to the end of observation. The potential interest of our study was also that patients enrolled in our study were outpatients that have to be considered at community levels.
CRP levels and ESR values signiWcantly decreased and spinal mobility, as measured by Schober's test, signiWcantly improved in patients undergoing both treatments. The results of this randomised study suggest that treatment with both etanercept and inXiximab is eVective, safe, and well tolerated in patients with AS. Patients with AS, in fact, were treated continuously and we did not observed any reduction in eYcacy with both treatments. 
